Stock listing
NASDAQ:TRDA Entrada Therapeutics, Inc. Stock
Home listing (NASDAQ) of Entrada Therapeutics, Inc.
Follow Entrada Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TRDA
$4.35 USD -0.68 (-13.5%)
Close on Nov 20, 2026
- Day range
- $4.32 – $4.58 USDNov 20, 2026
- Volume
- 347,920 sharesNov 20, 2026
- Market cap
- $170.3M USDAt the close on Nov 20, 2026 · price × 39.15M shares outstanding
- 52-week range
- $4.11 – $16.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.22M USDMedian day 371,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TRDA · Home | $4.35 USD | -0.68 (-13.5%) | 347,920 | $4.55 | $4.58 | $4.32 | $5.03 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TRDA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.35 | -0.68 | -13.5% | $4.55 | $4.58 | $4.32 | 347,920 | |
| $5.03 | +0.07 | +1.4% | $4.94 | $5.50 | $4.81 | 815,227 | |
| $4.96 | -0.04 | -0.8% | $5.04 | $5.435 | $4.91 | 432,577 | |
| $5.00 | -0.09 | -1.8% | $5.00 | $5.22 | $4.84 | 607,027 | |
| $5.09 | -0.08 | -1.5% | $5.17 | $5.245 | $4.91 | 791,634 | |
| $5.17 | -0.27 | -5.0% | $5.33 | $5.425 | $4.94 | 808,660 | |
| $5.44 | +0.19 | +3.6% | $5.25 | $5.49 | $4.961 | 760,792 | |
| $5.25 | +0.56 | +11.9% | $4.64 | $5.29 | $4.64 | 582,088 | |
| $4.69 | -0.20 | -4.1% | $4.85 | $4.89 | $4.543 | 500,223 | |
| $4.89 | +0.34 | +7.5% | $4.60 | $4.91 | $4.535 | 486,475 | |
| $4.55 | -0.51 | -10.1% | $5.05 | $5.068 | $4.52 | 305,203 | |
| $5.06 | +0.34 | +7.2% | $4.83 | $5.125 | $4.605 | 497,633 | |
| $4.72 | -0.39 | -7.6% | $5.08 | $5.08 | $4.615 | 563,121 | |
| $5.11 | +0.575 | +12.7% | $4.58 | $5.13 | $4.44 | 651,953 | |
| $4.535 | +0.135 | +3.1% | $4.37 | $4.545 | $4.26 | 317,344 | |
| $4.40 | -0.44 | -9.1% | $4.76 | $5.07 | $4.35 | 479,051 | |
| $4.84 | +0.43 | +9.8% | $4.38 | $4.88 | $4.33 | 409,094 | |
| $4.41 | -0.34 | -7.2% | $4.72 | $4.85 | $4.36 | 413,453 | |
| $4.75 | +0.34 | +7.7% | $4.46 | $4.945 | $4.46 | 617,085 | |
| $4.41 | -0.32 | -6.8% | $4.67 | $4.695 | $4.385 | 191,500 | |
| $4.73 | +0.08 | +1.7% | $4.71 | $4.78 | $4.555 | 462,100 | |
| $4.65 | -0.34 | -6.8% | $5.02 | $5.035 | $4.60 | 323,800 | |
| $4.99 | +0.17 | +3.5% | $4.81 | $5.27 | $4.79 | 403,100 | |
| $4.82 | +0.45 | +10.3% | $4.36 | $4.84 | $4.27 | 585,600 | |
| $4.37 | -0.41 | -8.6% | $4.79 | $4.85 | $4.345 | 371,800 | |
| $4.78 | +0.23 | +5.1% | $4.52 | $4.96 | $4.425 | 514,800 | |
| $4.55 | -0.31 | -6.4% | $4.69 | $4.77 | $4.109 | 740,100 | |
| $4.86 | -0.64 | -11.6% | $5.50 | $5.56 | $4.83 | 255,200 | |
| $5.50 | -0.17 | -3.0% | $5.64 | $5.69 | $5.48 | 198,600 | |
| $5.67 | +0.14 | +2.5% | $5.52 | $5.75 | $5.44 | 209,400 | |
| $5.53 | -0.08 | -1.4% | $5.52 | $5.59 | $5.25 | 361,500 | |
| $5.61 | +0.19 | +3.5% | $5.33 | $5.66 | $5.30 | 297,400 | |
| $5.42 | -0.06 | -1.1% | $5.52 | $5.52 | $5.25 | 315,900 | |
| $5.48 | +0.10 | +1.9% | $5.38 | $5.48 | $5.15 | 463,800 | |
| $5.38 | -0.30 | -5.3% | $5.77 | $6.22 | $5.17 | 463,700 | |
| $5.68 | -0.67 | -10.6% | $6.32 | $6.36 | $5.60 | 425,100 | |
| $6.35 | +0.09 | +1.4% | $6.20 | $6.39 | $6.125 | 239,900 | |
| $6.26 | +0.04 | +0.6% | $6.25 | $6.43 | $6.08 | 268,600 | |
| $6.22 | +0.06 | +1.0% | $6.13 | $6.24 | $5.925 | 442,600 | |
| $6.16 | -0.06 | -1.0% | $6.23 | $6.245 | $6.01 | 374,000 | |
| $6.22 | -0.28 | -4.3% | $6.47 | $6.47 | $6.14 | 319,100 | |
| $6.50 | -0.21 | -3.1% | $6.71 | $6.71 | $6.37 | 282,800 | |
| $6.71 | +0.07 | +1.1% | $6.71 | $6.93 | $6.654 | 195,500 | |
| $6.64 | -0.11 | -1.6% | $6.81 | $6.81 | $6.455 | 375,300 | |
| $6.75 | -0.15 | -2.2% | $6.85 | $6.89 | $6.60 | 354,400 | |
| $6.90 | +0.01 | +0.1% | $6.91 | $7.05 | $6.665 | 297,400 | |
| $6.89 | +0.01 | +0.1% | $6.92 | $6.99 | $6.74 | 249,200 | |
| $6.88 | -0.17 | -2.4% | $7.05 | $7.05 | $6.67 | 247,800 | |
| $7.05 | +0.25 | +3.7% | $6.80 | $7.07 | $6.72 | 336,100 | |
| $6.80 | +0.38 | +5.9% | $6.49 | $6.81 | $6.29 | 291,800 | |
| $6.42 | -0.69 | -9.7% | $7.00 | $7.175 | $6.38 | 448,100 | |
| $7.11 | -0.41 | -5.5% | $7.47 | $7.55 | $7.02 | 382,000 | |
| $7.52 | +0.39 | +5.5% | $7.02 | $7.70 | $6.945 | 514,200 | |
| $7.13 | -0.04 | -0.6% | $7.11 | $7.17 | $7.00 | 341,700 | |
| $7.17 | -0.13 | -1.8% | $7.31 | $7.423 | $7.04 | 395,600 | |
| $7.30 | +0.23 | +3.3% | $7.07 | $7.34 | $6.96 | 306,500 | |
| $7.07 | +0.02 | +0.3% | $6.95 | $7.179 | $6.80 | 205,500 | |
| $7.05 | +0.05 | +0.7% | $6.84 | $7.17 | $6.76 | 450,400 | |
| $7.00 | -0.27 | -3.7% | $7.18 | $7.24 | $6.935 | 111,600 | |
| $7.27 | +0.27 | +3.9% | $7.02 | $7.37 | $6.80 | 248,600 | |
| $7.00 | -0.62 | -8.1% | $7.55 | $7.64 | $6.954 | 229,300 | |
| $7.62 | +0.29 | +4.0% | $7.39 | $7.67 | $7.39 | 269,980 | |
| $7.33 | -0.24 | -3.2% | $7.58 | $7.58 | $7.12 | 184,249 | |
| $7.57 | -0.03 | -0.4% | $7.64 | $7.735 | $7.44 | 141,000 | |
| $7.60 | -0.18 | -2.3% | $7.76 | $7.765 | $7.30 | 250,000 |
- Ticker
- NASDAQ:TRDA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 50 slides
Latest news
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Nov 18, 2026
Closed $5.03 (+1.4%) on Nov 18, 2026
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $4.55 (-10.1%) on Nov 5, 2026
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Oct 21, 2026
Closed $4.65 (-6.8%) on Oct 21, 2026
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Oct 14, 2026
Closed $4.55 (-6.4%) on Oct 14, 2026
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Oct 14, 2026
Closed $4.55 (-6.4%) on Oct 14, 2026
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Sep 10, 2026
Closed $6.42 (-9.7%) on Sep 10, 2026
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Aug 5, 2026
Closed $7.06 (-2.5%) on Aug 5, 2026
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Jun 2, 2026
Closed $6.64 (-3.9%) on Jun 2, 2026
Entrada Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 75 in all · newest Nov 18, 2026 · oldest 2021
- Decks
- 9 decks · latest August 2026
Where Entrada Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TRDA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TRDA | BOATS | United States | USD |
Valuation
EV/sales 6.2× against a median of 16.4×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $24.60M USD
- P/E
- Loss
- EV/sales
- 6.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- 57.5%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.43
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. · NASDAQ:TRDA | US$170.3M | US$24.60M | n/a | 6.2× | n/a | 0.9× | n/a | 0.2× | 1.43 |
| Korro Bio, Inc. · NASDAQ:KRRO | US$179.4M | US$74.36M | n/a | 57.6× | n/a | 2.0× | n/a | 0.0× | 1.46 |
| Vogenx Inc · NASDAQ:VOGX | US$176.3M | US$94.21M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| MediWound Ltd. · NASDAQ:MDWD | US$175.5M | US$155.9M | n/a | 15.6× | n/a | 5.5× | −235.0% | 0.3× | 0.64 |
| Nanexa AB · OMXSTO:NANEXA | US$175.3M | US$170.3M | n/a | 51.4× | n/a | 13.5× | −72.5% | 0.0× | n/a |
| Compugen Ltd. · NASDAQ:CGEN | US$174.3M | US$59.55M | 4.8× | 0.8× | n/a | 2.1× | 47.9% | 0.0× | 1.49 |
| Guangzhou Innogen Pharmaceutical Group Co Ltd Class H · HKEX:2591 | US$170.8M | US$39.93M | n/a | 2.1× | n/a | 1.2× | −259.6% | 0.2× | n/a |
| SinoMab Bioscience Ltd. · HKEX:3681 | US$166.3M | US$172.4M | n/a | n/a | n/a | 3.1× | n/a | 0.7× | n/a |
| Prestige BioPharma Limited · KRX:950210 | US$164.7M | US$131.9M | n/a | 6.8× | n/a | 0.5× | −350.9% | 0.1× | n/a |
| Acepodia, Inc. · TPEX:6976 | US$162.7M | US$58.45M | n/a | 10,415× | n/a | 1.1× | n/a | 0.0× | n/a |
| TaiGen Biopharmaceuticals Holdings Limited · TPEX:4157 | US$161.1M | US$133.3M | 34.2× | 17.1× | 46.8× | 5.2× | 60.5% | 0.0× | n/a |
| Median of the others | US$172.5M | US$113.1M | 19.5× | 16.4× | 46.8× | 2.1× | −153.8% | 0.0× | 1.46 |
Forecasts
6 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.90 · 5 analysts
- Revenue, year to Dec 2026
- 5.49M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Dipal Doshi | Chief Executive Officer |
| Kory Wentworth | Chief Financial Officer |
| Natarajan Sethuraman | President of Research and Development |
| Nathan J. Dowden | President and Chief Operating Officer |
| Jared Cohen | General Counsel |
| Doug Snow | Head of Investor Relations |
| Kevin Healy | Senior Vice President, Regulatory Affairs |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Linea Aspesi | Chief People Officer |
Board
| Director | Role |
|---|---|
| Kush M. Parmar | Managing Partner, 5am Ventures (Board Chairman) |
| Bernhardt Zeiher | Industry Leader and Independent Director |
| Dipal Doshi | Chief Executive Officer |
| Gina Chapman | Industry Leader and Independent Director |
| Maha Radhakrishnan | Industry Leader and Independent Director |
| Mary Thistle | Industry Leader and Independent Director |
| Peter S. Kim | Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −10.1% |
| Q2 2026 | Aug 5, 2026 · Before open | −2.5% |
| Q1 2026 | May 7, 2026 · Before open | −57.3% |
| Q4 2025 | Feb 26, 2026 | −0.4% |
| Q3 2025 | Nov 6, 2025 · Before open | +0.1% |
| Q2 2025 | Aug 6, 2025 · Before open | +2.1% |
| Q1 2025 | May 8, 2025 · Before open | +5.6% |
| Q4 2024 | Mar 3, 2025 | −8.0% |
| Q3 2024 | Nov 5, 2024 · Before open | +4.8% |
| Q2 2024 | Aug 13, 2024 · Before open | +11.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | +2.8% |
| Q4 2023 | Mar 13, 2024 · Before open | +9.8% |
| Q3 2023 | Nov 7, 2023 · Before open | +8.6% |
| Q2 2023 | Aug 8, 2023 · Before open | +10.5% |
| Q1 2023 | May 10, 2023 · Before open | −2.1% |
| Q4 2022 | Mar 6, 2023 · Before open | −1.4% |
| Q3 2022 | Nov 7, 2022 · Before open | −10.0% |
| Q2 2022 | Aug 11, 2022 · Before open | +0.7% |
| Q1 2022 | May 12, 2022 · Before open | +10.3% |
| Q4 2021 | Mar 15, 2022 · Before open | +9.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 50 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 51 slides | May 19, 2026 |
| 2025 J.P. Morgan Healthcare Conference | Conference | 25 slides | Jan 15, 2025 |
| Targeted Intracellular Delivery Summit 2023 | Conference | 24 slides | Mar 8, 2023 |
| PPMD 2023 Annual Conference | Conference | 9 slides | 2023 |
| CureDuchenne FUTURES 2023 | Conference | 11 slides | 2023 |
| Boulder Peptide Symposium 2022 | Conference | 29 slides | Nov 10, 2022 |
| CureDuchenne Futures 2022 | Conference | 10 slides | 2022 |
| MDF 2022 | Conference | 12 slides | 2022 |
IPO
Priced at US$20.00 a share on Oct 28, 2021.
- Price
- US$20.00 a share
- Shares offered
- 9,075,000 shares of common stock
- Offering size
- US$181.5 million
- Underwriters' option
- Up to 1,361,250 more shares
- Listing
- TRDA on the Nasdaq Global Market
- Underwriters
- Goldman Sachs & Co. LLC, Cowen, Evercore ISI · In the order on the cover
- Shares delivered
- On or about Nov 2, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 6, 2021 |
| Filed publicly | Oct 8, 2021 |
| Amended once | Oct 25, 2021 |
| Shares registered with an exchange | Oct 26, 2021 |
| Declared effective by the SEC | Oct 28, 2021 |
| Final prospectus, with the price | Nov 1, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 1, 2021 |
| EFFECT · Notice that a registration is effective | Oct 28, 2021 |
| S-1MEF · Registration of more shares for the same offering | Oct 28, 2021 |
| CERT · Exchange's certificate of listing | Oct 27, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 26, 2021 |
| CORRESP · Letter to the SEC | Oct 26, 2021 |
| CORRESP · Letter to the SEC | Oct 26, 2021 |
| S-1/A · Registration statement, amended | Oct 25, 2021 |
| CORRESP · Letter to the SEC | Oct 8, 2021 |
| S-1 · Registration statement | Oct 8, 2021 |
All 15 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Sep 28, 2021 |
| DRSLTR · Letter to the SEC with a draft | Sep 15, 2021 |
| DRS/A · Draft registration statement, amended | Sep 15, 2021 |
| UPLOAD · Letter from the SEC | Sep 2, 2021 |
| DRS · Draft registration statement | Aug 6, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 1, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 25.4M | 210.8M | 129.0M | 25.3M | 0 | 0 | 0 |
| Cost of revenue | 4.10M | 3.77M | 99.9M | 1.90M | 1.12M | 326.0K | 104.0K |
| Gross profit | 21.3M | 210.8M | 129.0M | -1.90M | -1.12M | -326.0K | -104.0K |
| Research and development | 142.3M | 125.3M | 99.9M | 66.6M | 35.9M | 21.1M | 8.22M |
| Selling, general and administrative | 41.0M | 38.5M | 32.3M | 30.6M | 15.2M | 5.57M | 3.61M |
| Operating income | -157.9M | 47.0M | -3.16M | -97.2M | -51.1M | -26.7M | -11.8M |
| Depreciation and amortization | 4.10M | 3.77M | 2.84M | 1.90M | 1.12M | 326.0K | 104.0K |
| EBITDA | -153.8M | 50.8M | -321.0K | -95.4M | -50.0M | -26.3M | -11.7M |
| Interest expense | 2.63M | 31.0K | 0 | 0 | |||
| Income before tax | -142.8M | 66.5M | 12.1M | -94.6M | -51.2M | -26.5M | -5.10M |
| Income tax | 924.0K | 859.0K | 18.7M | 0 | 0 | 0 | -451.0K |
| Net income | -143.8M | 65.6M | -6.68M | -94.6M | -51.2M | -26.5M | -4.65M |
| Earnings per share, basic | -3.47 | 1.76 | -0.20 | -3.02 | -8.16 | -24.00 | -4.44 |
| Earnings per share, diluted | -3.47 | 1.68 | -0.20 | -3.02 | -8.16 | -24.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 90.4M | 101.2M | 67.6M | 45.2M | 291.1M | 39.0M | 16.8M |
| Short-term investments | 205.3M | 318.8M | 284.4M | 143.6M | 0 | ||
| Receivables | 2.58M | 3.68M | 5.88M | 872.0K | |||
| Inventory | 1 | ||||||
| Current assets | 306.3M | 440.0M | 369.8M | 209.9M | 298.7M | 39.9M | 17.4M |
| Property, plant and equipment | 7.31M | 10.9M | 11.2M | 7.68M | 6.26M | 3.04M | 801.0K |
| Total assets | 377.4M | 526.3M | 469.2M | 252.1M | 305.8M | 43.5M | 18.2M |
| Accounts payable | 2.29M | 4.26M | 3.28M | 5.99M | 706.0K | 1.60M | 710.0K |
| Current liabilities | 24.5M | 39.5M | 158.8M | 22.0M | 6.72M | 3.36M | 1.92M |
| Total debt | 50.9M | 59.2M | 68.2M | 25.9M | |||
| Total liabilities | 71.2M | 97.6M | 226.8M | 39.5M | 7.12M | 3.36M | 33.8M |
| Shareholders' equity | 306.1M | 428.7M | 242.4M | 212.6M | 298.7M | -41.5M | -15.5M |
| Shares outstanding | 38.3M | 37.6M | 33.4M | 31.4M | 31.2M | 1.24M | 1.05M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -128.5M | -41.6M | 139.8M | -93.8M | -50.9M | -25.6M | -10.8M |
| Capital spending | -1.04M | -3.16M | -5.61M | -2.89M | -4.58M | -2.32M | -630.0K |
| Free cash flow | -129.6M | -44.7M | 134.2M | -96.7M | -55.4M | -27.9M | -11.4M |
| Cash from investing | 116.8M | -27.8M | -138.4M | -148.7M | -4.58M | -2.32M | -630.0K |
| Cash from financing | 887.0K | 103.0M | 21.0M | 479.0K | 307.5M | 50.1M | 38.0K |
| Share buybacks | 462.0K | 574.0K | 443.0K | 284.0K | 191.1M | ||
| Change in cash | -10.8M | 33.6M | 22.4M | -242.0M | 252.0M | 22.2M | 16.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Aug 10, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Dec 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 1, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Nov 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 27, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 3, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2025 | Current report | SEC |
| 8-K · Current report | Jan 15, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 16, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 8, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 24, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 10, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Apr 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 19, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 19, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 17, 2024 | Other filings | SEC |
This page holds 200 of 474 filings. Open Filings
Cap table
Built by 6ix from Entrada Therapeutics, Inc.’s releases · as of Oct 31, 2026
- Common shares
- 39,150,334
- Fully diluted
- 39,150,334
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 39,150,334 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 39,150,334 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kush M. Parmar Other companies: Rallybio Corporation (Director · Jul 28, 2021 – May 15, 2024 · Past); Vor Biopharma Inc. (Director · Feb 4, 2021 – Jun 14, 2022 · Past); 5 01 Acquisition Corp (Co-CEO, Director · Oct 13, 2020 – Nov 30, 2020 · Past); Akouos Inc (Director · Jun 25, 2020 – Nov 30, 2022 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Sep 24, 2019 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 15, 2022 · Past); Scpharmaceuticals Inc (Director · Nov 16, 2017 – Jun 19, 2018 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jun 8, 2018 · Past) | Managing Partner, 5am Ventures (Board Chairman) · Since at least Oct 28, 2021 |
| Todd Foley Other companies: Aktis Oncology, Inc. (Co-founder and Chairman · Since at least Jan 8, 2026); Turmeric Acquisition Corp (President · Oct 15, 2020 – Oct 15, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 8, 2023 · Past); Rhythm Pharmaceuticals, Inc. (Director · Oct 4, 2017 – Mar 15, 2021 · Past); Chiasma Inc (Director · Jul 15, 2015 – Aug 5, 2021 · Past); Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Feb 4, 2014 · Past); EPIRUS Biopharmaceuticals Inc (Director · Dec 21, 2009 – May 23, 2012 · Past) | Director · Oct 28, 2021 – Jun 2, 2022 · Past |
| Mary Thistle Other companies: Aktis Oncology, Inc. (Independent Director · Since at least Jan 8, 2026); Cullinan Therapeutics, Inc. (Chair of the Compensation Committee · Since at least Aug 8, 2024); Vigil Neuroscience Inc (Director · Since at least Apr 18, 2022); Q32 Bio Inc. (Director · Since at least Mar 27, 2018); Alaunos Therapeutics, Inc. (Director · Nov 15, 2020 – Jun 6, 2023 · Past); Dimension Therapeutics (Chief Operating Officer · Feb 1, 2017 – Nov 7, 2017 · Past) | Industry Leader and Independent Director · Since at least Oct 28, 2021 |
| Carole Nuechterlein Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Aligos Therapeutics, Inc. (Director · Since at least Oct 15, 2020); Tango Therapeutics, Inc. (Director · Sep 2, 2020 – Sep 2, 2020 · Past); Tempest Therapeutics, Inc. (Director · Dec 7, 2018 – Jun 22, 2020 · Past); AveXis Inc (Director · Feb 10, 2016 – Feb 10, 2016 · Past) | Director · Oct 28, 2021 – Jun 2, 2022 · Past |
| Bernhardt G. Zeiher Other companies: Abeona Therapeutics Inc. (Director · Since at least Aug 8, 2024); Amylyx Pharmaceuticals, Inc. (Director · Since at least Mar 14, 2024) | Industry Leader and Independent Director · Since at least Apr 4, 2023 |
| John F Crowley Other companies: Intellia Therapeutics, Inc. (Director · Oct 2, 2020 – Jun 14, 2023 · Past); Amicus Therapeutics Inc (Executive Chairman, Director · Dec 31, 2011 – Mar 1, 2024 · Past) | Director · Oct 28, 2021 – Jun 8, 2023 · Past |
| Maha Radhakrishnan Other companies: Candel Therapeutics, Inc. (Director · Since at least Jun 4, 2025); Alto Neuroscience, Inc. (Director · Mar 8, 2024 – Mar 8, 2024 · Past) | Industry Leader and Independent Director · Since at least Jun 1, 2025 |
| Nerissa Kreher Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Jun 30, 2026); Rezolute, Inc. (Board Member · Since at least Jun 23, 2022) | Chief Medical Officer · Jul 1, 2022 – Sep 1, 2023 · Past |
| Dipal Doshi Other companies: Azenta, Inc. (Director · Since at least Jan 30, 2025) | Chief Executive Officer · Since at least Jun 27, 2022 |
| Gina Chapman Other companies: CARGO Therapeutics, Inc. (President & CEO, Director · Nov 9, 2023 – Mar 14, 2025 · Past) | Industry Leader and Independent Director · Since at least Sep 1, 2023 |
All 21 people
| Person | Seat |
|---|---|
| Kory Wentworth Other companies: Bluebird bio Inc (Principal Accounting Officer · Dec 18, 2017 – Aug 3, 2020 · Past) | Chief Financial Officer · Since at least Oct 28, 2021 |
| Caileigh Dougherty | Head of Investor Relations & Corporate Communications · Mar 24, 2025 – Nov 4, 2026 · Past |
| ContactCaileigh DoughertyHead | of Investor Relations & Corporate · Feb 3, 2025 – Nov 4, 2026 · Past |
| Doug Snow | Head of Investor Relations · Since at least Oct 21, 2026 |
| Jared Cohen | General Counsel · Since at least Nov 5, 2026 |
| Karla MacDonald | Chief Corporate Affairs Officer · Since at least May 6, 2026 |
| Kevin Healy | Senior Vice President, Regulatory Affairs · Since at least Nov 5, 2026 |
| Linea Aspesi | Chief People Officer · Since at least Oct 21, 2026 |
| Natarajan Sethuraman | President of Research and Development · Since at least Oct 28, 2021 |
| Nathan J. Dowden | President and Chief Operating Officer · Since at least Oct 28, 2021 |
| Peter S. Kim | Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University · Since at least Oct 28, 2021 |
Log in to ask 6ix AI your own questions about Entrada Therapeutics, Inc.